Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Graft Source

A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies

Bone Marrow Transplantation volume 50, pages 1519–1525 (2015)Cite this article

Subjects

Abstract

Umbilical cord blood (UCB) as an allogeneic transplant source is generally limited to units with pre-cryopreservation total nucleated cell (TNC) doses ⩾2.5 × 107 NC/kg. We prospectively investigated single UCB transplantation, with cord units as low as 1 × 107 NC/kg, all processed with post-thaw albumin–dextran dilution. We transplanted 104 adult patients with 84% having relapsed/refractory disease. The median TNC dose was 2.1 × 107 NC/kg (range: 1.0–4.4 × 107) and median CD34+ cell dose was 1.0 × 105/kg (range: 0.0–3.7 × 105/kg). Post-manipulation cell recovery and viability were 96% and 99%, respectively. Median times to neutrophil and platelet engraftment were 16 and 43 days, respectively. Univariate factors predicting neutrophil engraftment included TNC (P=0.03) and CD34+ cell dose (P=0.01). CD34+ dose predicted platelet engraftment (P<0.001). In multivariate analysis, CD34+ dose remained significant for neutrophil and platelet engraftment (P<0.0001 and P<0.0001, respectively). The 100-day and 1-year overall survival were 70% and 46%, respectively (95% confidence interval: 36%–56% at 1 year). The subset transplanted with 1–1.5 × 107 NC/kg had similar 100-day and 1-year survivals of 73% and 45%, respectively. Single-unit UCB transplantation using small units, processed as described, leads to favorable engraftment and acceptable outcomes in poor prognosis patients. CD34+ cell dose (⩾1.5 × 105/kg) helps predict faster engraftment and can aid in graft selection.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Ballen KK, Gluckman E, Broxmeyer HE . Umbilical cord Blood transplantation: the first 25 years and beyond. Blood 2013; 122: 491–498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Laroche V, McKenna DH, Moroff G, Schierman T, Kadidlo D, McCullough J . Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion 2005; 45: 1906–1916.

    Article  Google Scholar 

  3. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.

    Article  CAS  PubMed  Google Scholar 

  4. Van Besien K . Advances in umbilical cord blood transplantation - a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013. Leuk Lymphoma 2014; 55: 1735–1738.

    Article  CAS  PubMed  Google Scholar 

  5. Barker JN, Byam C, Scaradavou A . How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117: 2332–2339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Barker JN, Scaradavou A, Stevens CE . Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115: 1843–1849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653–660.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Garfall A, Kim H, Cutler C, Ho V, Koreth J, Armand P et al. Allele level matching at HLA-C or –DRB1 is associated with improved survival after reduced intensity cord blood transplantation. Blood 2012; 120: 2010a.

    Google Scholar 

  9. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C et al. Impact of donor-recipient HLA-matching at HLA A, B, C, and DRB1 on outcome after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12: 1214–1221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014; 123: 133–140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzeri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815–1822.

    Article  CAS  PubMed  Google Scholar 

  12. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.

    CAS  PubMed  Google Scholar 

  13. Wagner E, Duval M, Dalle JH, Morin H, Bizier S, Champagne J et al. Assessment of cord blood unit characteristics on the day of transplant: comparison with data issued by cord blood banks. Transfusion 2006; 46: 1190–1198.

    Article  PubMed  Google Scholar 

  14. Scaradavou A . Unrelated umbilical cord blood unit selection. Semin Hematol 2010; 47: 13–21.

    Article  PubMed  Google Scholar 

  15. Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kernan NA et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010; 16: 500–508.

    Article  PubMed  Google Scholar 

  16. Stiff PJ, Murgo AJ, Zaroulis CG, DeRisi MF, Clarkson BD . Unfractionated human marrow cell cryopreservation using dimethylsulfoxide and hydroxyethyl starch. Cryobiology 1983; 20: 17–24.

    Article  CAS  PubMed  Google Scholar 

  17. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  18. Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at http://www.cibmtr.org.

  19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–955.

    Article  PubMed  Google Scholar 

  21. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rocha V, Gluckman E . Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. B J Haematol 2009; 147: 262–274.

    Article  CAS  Google Scholar 

  23. Barker JN, Abboud M, Rice RD, Hawke R, Schaible A, Heller G et al. A ‘no-wash’ albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant 2009; 15: 1596–1602.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dahi PB, Ponce DM, Devlin S, Evans KL, Lubin MN, Gonzales AM et al. ‘No wash’ albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment. Biol Blood Marrow Transplant 2014; 20: 490–494.

    Article  PubMed  Google Scholar 

  25. Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica 2013; 98: 814–822.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006; 91: 223–230.

    PubMed  Google Scholar 

  27. Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant 2011; 46: 70–76.

    Article  CAS  PubMed  Google Scholar 

  28. Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F et al. Comparison of outcome after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eucord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28: 779–786.

    Article  CAS  PubMed  Google Scholar 

  29. Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W et al. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012; 47: 924–933.

    Article  CAS  PubMed  Google Scholar 

  30. Brunstein CG, Gutman JA, Weisdorf Dj, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693–4699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malasapina H et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1316–1326.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rocha V, Rio B, Garnier F, Renaud M, Sirvent A, Takahashi S et al. Reduced intensity conditioning regimen in single unrelated cord blood transplantation in adults with hematological malignant disorders. Blood 2006; 108: 897a.

    Google Scholar 

  33. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064–3070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119: 5591–5598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G et al. Reduced-intensity conditioning stem cell transplantation: a comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2012; 18: 805–812.

    Article  PubMed  Google Scholar 

  37. Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA et al. One-unit versus two-unit umbilical cord blood transplantation for hematologic cancers. N Engl J Med 2014; 371: 1685–1694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. De Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M et al. Cord blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305–2315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Brunstein CG, McKenna DH, DeFor TE, Sumstad D, Paul P, Weisdorf DJ et al. Complement fragment 3a priming of umbilical cord blood progenitors: safety profile. Biol Blood Marrow Transplant 2013; 19: 1474–1479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sureda A, Robinson S, Canals C, Carella AM, Boogaert MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the lymphoma working party of the European Group for blood and marrow transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  PubMed  Google Scholar 

  41. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    Article  CAS  PubMed  Google Scholar 

  42. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109–117.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sobol U, Rodriguez T, Smith S, Go A, Vimr R, Parthasarathy M et al. Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin Lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma 2014; 55: 1281–1287.

    Article  CAS  PubMed  Google Scholar 

  44. Jain S, Stiff PJ, Smith SE, Go A, Parthasarathy M, Rodriguez TE . Myeloablative conditioning with intravenous busulfan and pentostatin (Bu/Pent) Vs total body irradiation and cyclophosphamide (TBI/Cy) for elderly patients with acute myeloid leukemia or myelodysplasia. Blood 2013; 122: 5450–5450.

    Google Scholar 

Download references

Acknowledgements

We thank our transplant center’s nursing staff, advance practice nurses, research assistants, social workers and case managers for their invaluable ongoing contributions to patient care.

Author information

Authors and Affiliations

  1. Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL, USA

    U Sobol, A Go, S Kliethermes, S Bufalino, T Rodriguez, S Smith, M Parthasarathy & P Stiff

Authors
  1. U Sobol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kliethermes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Bufalino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Parthasarathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Stiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Stiff.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sobol, U., Go, A., Kliethermes, S. et al. A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 50, 1519–1525 (2015). https://doi.org/10.1038/bmt.2015.194

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.194

This article is cited by

Search

Advanced search

Quick links